Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

DKSH Technology Strengthens Its Business in Australia and New Zealand With the Acquisition of Bio-Strategy


DKSH Management Ltd. / Key word(s): Takeover
DKSH Technology Strengthens Its Business in Australia and New Zealand With the Acquisition of Bio-Strategy

02.11.2023 / 07:00 CET/CEST


Media release

DKSH has signed an agreement to acquire Bio-Strategy Limited (“Bio-Strategy”), the largest independent distributor of scientific instruments in Australia and New Zealand. With this acquisition, DKSH grows its Scientific Instrumentation business in line with Business Unit Technology’s strategy to build resilience and deliver profitable growth.

Zurich, Switzerland, November 2, 2023 – DKSH has announced today that it signed an agreement for the acquisition of Bio-Strategy, the largest independent distributor of scientific instruments in Australia and New Zealand, focusing primarily on life sciences, medical healthcare and environment agriculture segments.

 

Established 2003 and based in Melbourne, Bio-Strategy generates net sales of more than CHF 40 million1 at good profitability. With a team of over 100 people, the company serves renowned blue chip clients and distributes products and services to around 1,200 customers. DKSH acquires 100% of the business and its management team and employees will join DKSH’s Business Unit Technology.

 

Hanno Elbraechter, Head Business Unit Technology at DKSH, commented: “I am delighted with the acquisition of Bio-Strategy as an important addition to DKSH. The specific industry and application knowledge of the company will help us to solidify our position in two of Asia Pacific’s key markets. While complementing both DKSH Technology’s product portfolio and regional presence, the acquired expertise will enable us to create added value for our clients and customers.”

 

John Chesterfield, CEO of Bio-Strategy, said: “We are pleased about the combination with DKSH, one of Asia’s leading technology distribution players, marking the next big step in our 20-year journey. In addition to a wider regional reach and an enlarged product and service portfolio, our clients, customers, employees, and business partners will benefit from various synergies. We are excited about our shared future, to leverage our common expertise and to continue successfully serving our stakeholders.”

 

The closing of the transaction is expected during the fourth quarter of 2023 and is subject to certain conditions.

 

1 Exchange rate 1 Swiss Franc / 1.88 NZD

For further information, please contact:

 

DKSH Holding Ltd.

 

Till Leisner

Head, Group Investor Media Relations, Sustainability

Phone +41 44 386 7315 

[email protected]

 

Melanie Grüter

Manager Group Media Relations

Phone +41 44 386 7211

[email protected]

 



End of Media Release


Language: English
Company: DKSH Management Ltd.
Wiesenstrasse 8
8008 Zurich
Switzerland
Phone: 044 386 72 72
E-mail: [email protected]
Internet: www.dksh.com
ISIN: CH0126673539
Valor: 12667353
Listed: SIX Swiss Exchange
EQS News ID: 1763077

 
End of News EQS News Service

1763077  02.11.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1763077&application_name=news&site_id=sharewise
Like: 0
Teilen
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Rechtlicher Hinweis

Kommentare